December 18, 2022Russian Journal of CardiologyOpen Access

FCM therapy significantly increased global work index (826±314 vs 1041±354, p=0.0001) and LVEF (29.1±10.3 vs 35.4±11.1, p=0.001) at 3 months, with no significant changes in the control group.

View Full Paper

Ask AI

Bookmark

Why the study?

The study was conducted to assess non-invasive parameters of left ventricular myocardial work after ferric carboxymaltose therapy in patients with heart failure with reduced ejection fraction and iron deficiency.

Does intravenous ferric carboxymaltose improve left ventricular myocardial work and systolic function in patients with HFrEF and iron deficiency?

Population

35 patients with HFrEF and iron deficiency

Comparison

Intravenous FCM 1500 mg plus BMT vs BMT alone

Design

Randomized trial

Follow-up

3 months

Authors

ZKZhanna Kobalava АСА. Ф. Сафарова ALA. A. Lapshin

Discussion

Member takes

Overview

FCM effects on myocardial work parameters in HFrEF with ID are hypothesis-generating; larger prospective studies needed before any clinical role.

Structured PICO

Does intravenous ferric carboxymaltose improve left ventricular myocardial work and systolic function in patients with HFrEF and iron deficiency?

Population

35 patients with HFrEF (LVEF ≤40%) and iron deficiency, body >70 kg, receiving best medical therapy. Median age 67±11.7 years, 83% men.

Intervention

Intravenous ferric carboxymaltose 1500 mg in 2 injections with an interval of one week between injections, added to best medical therapy

Comparator

Best medical therapy without ferric carboxymaltose

Outcome

Non-invasive parameters of left ventricular myocardial work (global work index, global constructive work, global work efficiency) and LVEF at 3 monthssurrogate

Intravenous ferric carboxymaltose improves left ventricular systolic function and non-invasive myocardial work parameters in patients with HFrEF and iron deficiency.

Cite This Study

Kobalava et al. (2022) studied this question.

synapsesocial.com/papers/6a6f93ccabc331a858078ea6 https://doi.org/10.15829/1560-4071-2023-5310

View Full Paper

Ask AI

Bookmark

December 18, 2022Russian Journal of CardiologyOpen Access

FCM therapy significantly increased global work index (826±314 vs 1041±354, p=0.0001) and LVEF (29.1±10.3 vs 35.4±11.1, p=0.001) at 3 months, with no significant changes in the control group.

View Full Paper

Ask AI

Bookmark

Why the study?

Does intravenous ferric carboxymaltose improve left ventricular myocardial work and systolic function in patients with HFrEF and iron deficiency?

Population

35 patients with HFrEF and iron deficiency

Comparison

Intravenous FCM 1500 mg plus BMT vs BMT alone

Design

Randomized trial

Follow-up

3 months

Authors

ZKZhanna Kobalava АСА. Ф. Сафарова ALA. A. Lapshin

Discussion

Member takes

Overview

FCM effects on myocardial work parameters in HFrEF with ID are hypothesis-generating; larger prospective studies needed before any clinical role.

Structured PICO

Does intravenous ferric carboxymaltose improve left ventricular myocardial work and systolic function in patients with HFrEF and iron deficiency?

Population

35 patients with HFrEF (LVEF ≤40%) and iron deficiency, body >70 kg, receiving best medical therapy. Median age 67±11.7 years, 83% men.

Intervention

Intravenous ferric carboxymaltose 1500 mg in 2 injections with an interval of one week between injections, added to best medical therapy

Comparator

Best medical therapy without ferric carboxymaltose

Outcome

Non-invasive parameters of left ventricular myocardial work (global work index, global constructive work, global work efficiency) and LVEF at 3 monthssurrogate

Intravenous ferric carboxymaltose improves left ventricular systolic function and non-invasive myocardial work parameters in patients with HFrEF and iron deficiency.

Cite This Study

Kobalava et al. (2022) studied this question.

synapsesocial.com/papers/6a6f93ccabc331a858078ea6 https://doi.org/10.15829/1560-4071-2023-5310

View Full Paper

Ask AI

Bookmark